Navigation Links
PPTA Applauds Preserving Access to Orphan Drugs Acts
Date:6/14/2013

ANNAPOLIS, Md., June 14, 2013 /PRNewswire/ -- The Plasma Protein Therapeutics Association (PPTA) commends the Preserving Access to Orphan Drugs Acts, bipartisan legislation that makes an important policy clarification and will remove a barrier to research and development of rare disease therapies.

Representative Jim Gerlach (R-PA), introduced H.R. 2315 with lead cosponsor Rep. Richard Neal (D-MA), and Senator Patrick Toomey (R-PA), introduced an identical bill, S. 1128, with lead cosponsors Sens. Robert Casey (D-PA) and Mike Crapo (R-ID). "Representative Gerlach and Senator Toomey have demonstrated exceptional leadership and commitment to the rare disease community with this legislation," Julie Birkofer, PPTA Senior Vice President, North America said.

The budget neutral bills will clarify the orphan drug exclusion from the annual pharmaceutical fee by basing the exclusion on whether the therapy is solely approved for marketing by the Food and Drug Administration (FDA) to treat a rare disease or condition. Under current law, a product only is excluded from paying the annual fee if it has claimed the Orphan Drug Act tax credit. This has left many plasma protein therapies unable to qualify for the exclusion and disproportionately affects these lifesaving rare disease therapies. In the U.S., a rare disease or condition is generally defined as one affecting less than 200,000 persons.

"Claiming of the Orphan Drug Act tax credit is not the best way to define all rare disease therapies; many are left out of the exclusion despite treating orphan conditions," Birkofer said. "The optimal way to meet the needs of patients who rely on PPTs is to clarify the provision in the Affordable Care Act to recognize rare diseases and this bill achieves that," she added.

Plasma protein therapies include plasma-derived therapies and recombinant blood clotting factors. These unique, non-interchangeable biological products for which no generics or substitutions exist are used to treat bleeding disorders, primary immunodeficiency diseases, alpha-1 antitrypsin deficiency, and certain rare neurological disorders

About PPTA
PPTA represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. PPTA member companies produce approximately 80% of the therapies in the U.S. and 60% of those manufactured in Europe. PPTA works globally to advocate for access to and affordability of therapies; engage in constructive dialogue with regulatory authorities and collaborate with patient organizations. PPTA also administers standards and programs that help ensure the quality and safety of plasma, manufacturing, donors and patients.


'/>"/>
SOURCE Plasma Protein Therapeutics Association (PPTA)
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CHPA Applauds Alabama Senates Passage of Anti-Meth Bill
2. CHPA Applauds Alabamas Adoption Of HB 363
3. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
4. CHPA Applauds Arizonas Adoption Of HB 2263
5. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
6. Obesity Care Continuum (OCC) Applauds FDA for Approval of New Obesity Drug
7. Novation Applauds FDAs Unique Device Identification Rule
8. American Academy of Pain Medicine Applauds FDA Action to Enhance Patient Safety on Prescribing Opioids; Offers AAPM Safe Opioid Prescribing Course as Educational Model
9. Mylan Applauds Signing of Landmark "Food and Drug Administration Safety and Innovation Act"
10. ADVENTRX Applauds Inclusion of Rare Diseases Provisions in the FDA Safety and Innovation Act
11. CRN Applauds Introduction Of Designer Anabolic Steroid Control Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... Hologic, Inc. (Nasdaq: HOLX ) ... second quarter ended April 1, 2017 .   GAAP ... compared to the prior year period as the sale ... gain, while non-GAAP diluted EPS of $0.50 increased 6.4%.  ... constant currency terms.  Excluding the effects of blood screening ...
(Date:5/10/2017)... , May 10, 2017 Radiology has ... unfortunately its costs have also spiraled to the number ... sent to radiology than ever before as the most ... For a patient with lower back pain an MRI ... anatomical reason for pain, resulting in entirely different treatment ...
(Date:5/9/2017)...  Demonstrating its commitment to representing research- based ... Pharmaceutical Research and Manufacturers of America (PhRMA) today ... now have to meet new research and development ... join PhRMA. "By putting in place ... clear message that being a member of PhRMA ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... Altec Products, ... in nVerge 2017 – a one-day technology conference in San Diego, CA. , ... which allows users to fully utilize and enhance their Sage ERP solutions by providing ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Manju R. Kejriwal, a leading Ohio ... with or without a referral. Dr. Kejriwal understands the emotional and financial toll traditional ... in Cincinnati, OH. Patients no longer need to feel the esthetic effects of wires ...
(Date:5/24/2017)... ... May 24, 2017 , ... Myers Jackson is well ... the ability to sell luxury homes anywhere on the planet. The luxury home market ... from Hattiesburg to Houston city-scapes. A quick search of “11 Spyglass Hill Auction will ...
(Date:5/24/2017)... ... May 24, 2017 , ... Medic CE , a Career ... about Pediatric Septic Shock” hosted by the Journal of Emergency Medical Services (JEMS). The ... time, will be presented by Captain Rommie Duckworth, LP, a career fire captain as ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... is offering holistic pediatric dentistry options for its patients on Long Island, New ... patient’s entire physical well being, and is one of the biggest trends in ...
Breaking Medicine News(10 mins):